BofA raises Ligand Pharma stock price target on XOMA acquisition By Investing.com

BofA Securities raised its Ligand Pharmaceuticals price target to $260 from $250 and kept a Buy rating, citing the $739 million XOMA acquisition and expanded portfolio of about 120 programs, including 7 commercial assets and 14 late-stage programs. The article also notes strong recent operating results, with Q4 revenue of $59.7 million versus $55.6 million expected and adjusted EPS of $2.02 versus $1.50 consensus. While some investors may be cautious about the deal size, analysts see the risk-reward as skewed to the upside.

Analysis

LGND is behaving less like a simple royalty stream and more like a capital allocator with embedded duration optionality. The XOMA transaction should compress earnings volatility by broadening the royalty base, but the more important second-order effect is that it turns LGND into a “platform premium” story: once investors accept that the company can continuously recycle capital into accretive royalty assets, the market may start valuing it on deployable capital velocity rather than near-term EPS alone. That said, the stock already prices in a very high execution rate, so incremental upside now depends on closing risk, financing discipline, and whether the acquired portfolio actually contributes across multiple cycles rather than just one-quarter beats.

The near-term risk is not operating performance; it is multiple compression if the deal math looks too financial-engineering heavy or if integration distracts from organic royalty origination. Because the close is expected months out, this is a “watch the spread, not the print” setup: if LGND trades materially above the implied deal-adjusted value, the market is signaling confidence in a roll-up rerating; if it stalls or derates, the consensus is probably overestimating how much recurring royalty growth can offset dilution from the acquisition premium and contingent consideration.

The contrarian angle is that the market may be underappreciating how much this deal increases LGND’s exposure to binary clinical/regulatory outcomes embedded in a larger number of smaller assets. More programs can mean more diversification, but it can also mean more hidden correlation to late-stage biotech sentiment and a higher probability of negative surprise leakage into reported royalty growth. In other words, the stock may look safer because it is broader, while economically it may become more levered to the overall biotech funding cycle and to investor appetite for acquisitive IP-platform names.

Key Decisions for Investors

• Stay long LGND only on pullbacks into deal skepticism over the next 1-3 months; upside is driven by rerating if management shows disciplined capital deployment, but chasing strength here risks paying peak confidence multiples.
• Use a call spread rather than outright stock for the next 6-9 months (e.g., LGND 240/280 call spread) to express upside from a successful close while capping downside from any acquisition/multiple disappointment.
• Pair trade: long LGND / short a basket of weaker royalty or late-stage biotech balance-sheet names over the next 2 quarters to isolate platform-quality versus financing-fragility; the trade works if capital keeps rotating into durable IP income.
• If LGND rallies another 10-15% before close, trim 25-33% of exposure and re-add after transaction confirmation; the main risk/reward inflection is post-announcement execution, not headline optimism.